drugset
drugset / Trial / NCT02117401

A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients

NCT02117401 ↗

Phase 4 Completed 1152 enrolled Jiangsu Nhwa Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the effect and safety of mivacurium chloride in pediatric patients.

Timeline

Start
2012-01
Primary completion
2013-06
Completion
2013-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mivacurium Small molecule 0.15 mg/kg Intravenous
Subject Mivacurium Small molecule 0.2 mg/kg Intravenous
Subject Mivacurium Small molecule 0.25 mg/kg Intravenous
Background Ketamine Small molecule 100 mg Intramuscular
Background Midazolam Small molecule 0.5 mg/kg Oral
Background Midazolam Small molecule 10 mg Oral
Background Propofol Small molecule 50 ug/kg —
Background Propofol Small molecule 100 ug/kg —
Background Propofol Small molecule 2 mg/kg —
Background Propofol Small molecule 3 mg/kg —
Background Remifentanil Small molecule 0.1 ug/kg —
Background Remifentanil Small molecule 0.3 ug/kg —
Background Remifentanil Small molecule 2 ug/kg —

Indications

No indication recorded.